retatrutide clinical trial weight loss results After 40: Realistic Timelines The result of the late

This muscle loss undermines metabolic rate, functional capacity, and long-term weight maintenance

The SURMOUNT-5 trial, published in The New England Journal of Medicine , directly compared tirzepatide to semaglutide and found tirzepatide produced 47% greater relative weight loss at 72 weeks, 20.2% of body weight versus 13.7%

Otherwise, they experience the same side effects and risks as adults on GLP-1 medications

The cost-per-percentage-point-of-weight-loss calculation is revealing

They contain FDA-approved active ingredients but have not undergone FDA review for safety, efficacy, or quality as finished products

See our retatrutide dosage guide for how the dose increase works